Pfizer vaccine appears effective against UK variant
The COVID-19 vaccine developed by Pfizer and BioNTech is likely to protect against a more infectious variant of the virus, which was discovered in Britain and has spread around the world, according to results of further lab tests released on Wednesday.
Health Secretary Matt Hancock said there was “exciting new data” showing the effectiveness of the vaccines.He told a Downing Street press conference the data showed that “a single shot of either the Oxford/AstraZeneca vaccine or of the Pfizer vaccine works against severe infection among the over-70s with a more than 80% reduction in hospitalisations”.
Credit: PA - Press Association STUDIO Duration: 01:00Published
New data shows that a single jab of either the Oxford-AstraZeneca or the Pfizer-BioNTech Covid jab reduces the chance of needing hospital treatment by over 80%. Health Secretary Matt Hancock told a Downing Street press conference that "a single shot of either the Oxford/AstraZeneca vaccine or of the Pfizer vaccine works against severe infection among the over-70s with a more than 80% reduction in hospitalisations". He added that the data shows "the protection that you get from catching Covid 35 days after a first jab is even slightly better for the Oxford jab than for Pfizer, albeit both results are clearly very strong."
Report by Thomasl. Like us on Facebook at http://www.facebook.com/itn and follow us on Twitter at http://twitter.com/itn
Researchers carried out regular tests on staff at Addenbrooke's Hospital in Cambridge, and found that as well as slowing transmission of Covid-19, the jab also prevented people from getting seriously ill if they caught the virus after being vaccinated.
Credit: Cover Video STUDIO Duration: 01:07Published
A man who was diagnosed with a one-in-a-million disease more than 20 years ago received his Covid vaccine from the same “guardian angel” doctor who saved his life when he was younger.Andy Barr, 44, was diagnosed with Goodpasture syndrome – an autoimmune disease in which antibodies attack the kidney and lungs – when he was 21, thanks to a doctor who by chance was doing a rotation at the Gloucester Royal hospital where he was being treated.
Credit: PA - Press Association STUDIO Duration: 02:04Published
The UK will examine European Union proposals for a vaccine passport in the hope of reviving international travel for the summer holidays.
Health Secretary Matt Hancock said Britain was working with the EU and countries around the world on the issue.
But England's Deputy Chief Medical Officer Professor Jonathan Van-Tam said there was still "great uncertainty" around holidays on the continent, partly because the EU’s vaccination programmes were behind the UK's.
European Commission President Ursula von der Leyen said plans for a "digital green pass" will be set out this month, which would allow people to prove they have had a jab or show the results of Covid tests. Report by Avagninag. Like us on Facebook at http://www.facebook.com/itn and follow us on Twitter at http://twitter.com/itn
Initial deliveries of the newly approved Johnson & Johnson COVID-19 vaccine should start on Tuesday, senior Biden administration officials said on Sunday, saying they hoped to boost lagging vaccination rates among minorities. Bryan Wood reports.
A single dose of the Pfizer-BioNTech coronavirus vaccine reduces the risk of asymptomatic infections, helping to stem transmission, research suggests.The UK has approved three coronavirus jabs – Pfizer-BioNTech, AstraZeneca-University of Oxford and Moderna – after studies demonstrated they significantly ward off severe disease.With not everyone able to be immunised, or producing a strong immune response as a result of their vaccination, questions lingered as to whether the jabs prevented the infection itself.Asymptomatic infections are particularly important amid the pandemic, given these individuals do not know to isolate and may unwittingly transmit the coronavirus even when they speak.To learn more, medics from the Cambridge University Hospitals NHS Foundation Trust (CUH) swabbed the site's vaccinated and unvaccinated healthcare workers over two weeks.Results suggest the risk of an asymptomatic infection decreases by four times more than 12 days after a worker received the Pfizer-BioNTech jab.
New research suggests people of all ages who have had two jabs of the Pfizer-BioNTech coronavirus vaccine produce high numbers of antibodies.
The Imperial College London and Ipsos Mori study, React-2, said data shows that 87.9% of people over the age of 80 tested positive for antibodies after two doses.
That figure rose to 95.5% for those under 60 and 100% in those aged under 30.
However, researchers warned there was not enough data to say how protected someone may be from the virus based on a positive antibody test result, and it did not mean they were immune. Report by Avagninag. Like us on Facebook at http://www.facebook.com/itn and follow us on Twitter at http://twitter.com/itn